|
Sign In to gain access to subscriptions and/or personal tools.
|
Do antidepressants cause suicidality in children? A Bayesian meta-analysis
Eloise E Kaizar
Department of Statistics, Carnegie Mellon University, Pittsburgh, PA, USA
Joel B Greenhouse
Department of Statistics, Carnegie Mellon University, Pittsburgh, PA 15217, USA; joel{at}stat.cmu.edu; Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Howard Seltman
Department of Statistics, Carnegie Mellon University, Pittsburgh, PA, USA
Kelly Kelleher
Department of Pediatrics, Ohio State University and Children's Research Institute, Columbus, OH, USA
Background To quantify the risk of suicidal behavior/ideation (suicidality) for children who use antidepressants, the FDA collected randomized placebo-controlled trials of antidepressant efficacy in children. Although none of the 4487 children completed suicide, 1.7% exhibited suicidality. The FDA meta-analyzed these studies and found sufficient evidence of an increased risk to require a black-box warning on antidepressants for children.
Purpose The FDA considered different drug formulations and psychiatric diagnoses to be equivalent in their effect on suicidality. If this assumption does not hold, the FDA analysis may have underestimated the variance of the risk estimate. We investigate the consequences of relaxing these assumptions.
Methods We extend the FDA analysis using a Bayesian hierarchical model that allows for a study-level component of variability and facilitates extensive sensitivity analyses.
Results We found an association between antidepressant use and an increased risk of suicidality in studies where the diagnosis was major depressive disorder (odds ratio 2.3 [1.3, 3.8]), and where the antidepressant was an SSRI (odds ratio 2.2 [1.3, 3.6]). We did not find evidence for such an association in the complement sets of trials. Although the results based on the hierarchical model are insensitive to model perturbations, the robustness of the FDA's meta-analysis to model assumptions is less clear. These data have limited generalizability due to exclusion of patients with baseline risk of suicide and the use of relatively short duration trials.
Conclusions Because of model specification and interpretation issues raised in this paper, we conclude that the evidence supporting a causal link between antidepressant use and suicidality in children is weak. The use of Bayesian hierarchical models for meta-analysis has facilitated the incorporation of potentially important sources of variability and the use of sensitivity analysis to assess the consequences of model specifications and their impact on important regulatory decisions.
References
- 1. Medco press release: Pediatric antidepressant use shows substantial decline over past year. http://www.corporate-ir.net/ireye/irsite.zhtml? ticker MHS&script 410&layout-6&item id 668973&sstring anti depressant, (1 February 2005). Retrieved 10 June 2005.
- 2. Leslie LK, Newman TB, Chesney J, Perrin JM. The Food and Drug Administration's deliberations on antidepressant use in pediatric patients. Pediatrics 2005; 116: 195–204.[Abstract/Free Full Text]
- 3. Roberts RE, Attkisson CC, Rosenblatt A.Prevalence of psychopathology among children and adolescents. Am J Psychiatry 1998; 155: 715–725.[Abstract/Free Full Text]
- 4. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990; 147: 207–210.[Abstract/Free Full Text]
- 5. Healy D.Let them eat prozac: the unhealthy relationship between the pharmaceutical industry and depression. New York University Press, 2004.
- 6. Treatment for Adolescents with Depression Study Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for adolescents with depression study (TADS) randomized controlled trial. JAMA 2004; 292: 807–820.[Abstract/Free Full Text]
- 7. Hammad TA. Review and evaluaton of clinical data. http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf, (August 2004). Retrieved 10 June 2005.
- 8. Hammad TA. Results of the analysis of suicidality in pediatric trials of newer antidepressants. http://www.fda.gov/ohrms/dockets/ac/04/slides/2004-4065S1_08_FDA-Hammad.ppt (September 2004). Retrieved 10 June 2005.
- 9. FDA. Characteristics of pediatric antidepressant trials. http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065B1_29_Handout-Tables.pdf, (September 2004). Handout at the September advisory committees meeting. Retrieved 10 June 2005.
- 10. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F.Methods for meta-analysis in medical research. Wiley, 2000.
- 11. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986; 7: 177–188.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- 12. Smith TC, Spiegelhalter DJ, Thomas A. Bayesian approaches to random-effects meta-analysis: A comparative study. Statistics in Medicine 1995; 14: 2685–2299.[Web of Science][Medline]
[Order article via Infotrieve]
- 13. Spiegelhalter DJ, Best NG, Carlin BP, van der Linde A. Bayesian measures of model complexity and fit (Pkg: P583-639). Journal of the Royal Statistical Society, Series B: Statistical Methodology 2002; 64: 583–616.
- 14. Gelman A, Carlin JB, Stern HS, Rubin DB.Bayesian data analysis second edition. Chapman and Hall/CRC, 2003.
- 15. Warn DE, Thompson SG, Spiegelhalter DJ. Bayesian random effects meta-analysis of trials with binary outcomes: methods for absolute risk difference and relative risk scales. Statistics in Medicine 2002; 21: 1601–1123.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- 16. Dempster AP, Rubin DB, Tsutakawa RK.Estimation in covariance components models. Journal of the American Statistical Association 1981; 76: 341–353.
- 17. Gilks WR, Thomas A, Spiegelhalter DJ. A language and program for complex Bayesian modelling. The Statistician: Journal of the Institute of Statisticians 1994; 43: 169–177.
- 18. DuMouchel W. Hierarchical Bayes linear models for meta-analysis. Tech. Rep. 27, National Institute of Statistical Sciences, September 1994.
- 19. Greenhouse JB, Seltman H. Using prior distributions to synthesize historical evidence: Comments on the Goodman-Sladky case study of IVIg in Guillan-Barré syndrome. Clinical Trials: Journal of the Society for Clinical Trials 2005; 2: 311–318.
- 20. Spiegelhalter DJ, Abrams KR, Myles JP.Bayesian approaches to clinical trials and health-care evaluation. Wiley, 2004.
- 21. Chaloner K. Elicitation of prior distributions. In Berry D, Stangl D eds. Bayesian biostatistics. Marcel Dekker, 1996: 141–156.
- 22. Garthwaithe PH, Kadane JB, O'Hagan A. Statistical methods for eliciting probability distributions. Journal of the American Statistical Association 2005; 100: 680–700.
- 23. Kass RE, Greenhouse JB. Comments on ‘Investigating therapies of potentially great benefit: ECMO'. Statistical Science 1989; 4: 310–317.
- 24. Agresti A.Categorical data analysis. John Wiley & Sons, 1990: 462–464.
- 25. Lieberman JA, Greenhouse JB, Hamer R et al.Comparing the effects of antidepressants: Consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology 2005; 30: 445–460.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- 26. Food and Drug Administration Center for Drug Evaluation and Research. Summary minutes of the CDER psychopharmacologic drugs advisory committee and the FDA pediatric advisory committee. http://www.fda.gov/ohrms/dockets/ac/04/minutes/2004-4065M1_Final.doc, (September 2004). Retrieved 10 June 2005.
- 27. Iyengar S, Greenhouse J. Selection models and the file-drawer problem. Statistical Science 1988; 3: 109–117.
- 28. Rosenthal R. The ‘file-drawer problem' and tolerance for null results. Psychological Bulletin 1979; 86: 638–641.
- 29. Young EA, Coryell W. Suicide and the hypothalamic-pituitary-adrenal axis. Lancet 2005; 366: 959–961.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- 30. Gibbons RD, Hur K, Bhawnik DK, Mann JJ. The relationship between antidepressant medication use and rate of suicide. Archives of General Psychiatry 2005; 62: 165–172.[Abstract/Free Full Text]
- 31. Brent DA. Antidepressants and pediatric depression – the risk of doing nothing. New England Journal of Medicine 2004; 351: 1598–1601.[Free Full Text]
- 32. Greenhouse J, Kelleher K. Thinking outside the (black) box: Antidepressants, suicidality and research synthesis. Pediatrics 2005; 116: 231–233.[Free Full Text]
- 33. Cornfield J. Recent methodological contributions to clinical trials. American Journal of Epidemiology 1976; 104: 408–421.[Free Full Text]
Clinical Trials, Vol. 3, No. 2,
73-98 (2006)
DOI: 10.1191/1740774506cn139oa
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
S. B. Williams, E. A. O'Connor, M. Eder, and E. P. Whitlock
Screening for Child and Adolescent Depression in Primary Care Settings: A Systematic Evidence Review for the US Preventive Services Task Force
Pediatrics,
April 1, 2009;
123(4):
e716 - e735.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Heneghan, A. S. Garner, A. Storfer-Isser, K. Kortepeter, R. E. K. Stein, and S. McCue Horwitz
Use of Selective Serotonin Reuptake Inhibitors by Pediatricians: Comparing Attitudes of Primary Care Pediatricians and Child and Adolescent Psychiatrists
Clinical Pediatrics,
March 1, 2008;
47(2):
148 - 154.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. A. Bridge, S. Iyengar, C. B. Salary, R. P. Barbe, B. Birmaher, H. A. Pincus, L. Ren, and D. A. Brent
Clinical Response and Risk for Reported Suicidal Ideation and Suicide Attempts in Pediatric Antidepressant Treatment: A Meta-analysis of Randomized Controlled Trials
JAMA,
April 18, 2007;
297(15):
1683 - 1696.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
